



UCI 07-40

Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

UCI 15-82

A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease (Ou)

UCI 17-90

A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy (Zhu)

CMET

PD1/PD-L1

Lung Cancer Trials

EGFR/ HER 2

UCI 17-83

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (Zhu)

UCI 17-101

A Phase 2 Study of Pozitotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1) (Zhu)

UCI 18-18

A Randomized, Double-Blind, Phase 3 study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR mutated Tumor in Metastatic Non-Squamous Non-Small Lung Cancer (NSCLC) Participants (KEYNOTE-789) (Ou)

****UCI 18-42**

A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-Small Cell Lung Cancer (Zhu)



Lung Cancer Clinical Trials

UCI 18-22

A Phase I/II study of Ceritinib + Trametinib in Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (Ou)

**UCI 18-26

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (Ou)

**UCI 18-78

A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (Ou)

UCI 16-79

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Ejadi)

ALK/ ROS 1

KRAS G12C

Lung Cancer Trials

RET

NTRK1-3

UCI 17-100

A Phase 1/2 Study of alectinib in RET-rearranged non-small cell lung cancer or RETmutated thyroid cancer (Ou)

UCI 16-96

A Phase 1 Study with Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors (Zhu)

**UCI 18-21

A Phase I/II Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) (Ou)

UCI 16-79

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Ejadi)